ANAleksandra A. Nezhelskaya

Aleksandra A. Nezhelskaya

*This is an algorithmically generated author record based on publicly available information.

Aleksandra A. Nezhelskaya has a total of 36 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Quality of life in patients with cerebral palsy: literature review

    by Aleksandra A. Nezhelskaya, Alexey L. Kurenkov, Lyudmila M. Kuzenkova, Bella I. Bursagova

    Currently, much attention is paid to the study of the quality of life of patients suffering from chronic pathology. The quality of life is closely related to the patient’s awareness of confidence and well-being in many areas, not only with the perception of their physical condition, but also in many other aspects of life including social interactions, emotional experiences, spiritual values and in other areas. Cerebral palsy is a severe chronic disabling disease with the presence of not only motor disorders, but also speech, cognitive, mental health problems that lead to social maladaptation. There are special tools for quality of life assessment, which include various questionnaires. Some of them, for example, the Pediatric Quality of Life Inventory (PedsQL) has a special module “Cerebral palsy”, the following problems are covered: daily activities, movement and balance, pain, fatigue, eating. From the age of 5 years, the block «speech and communication», «school classes» is added. Such questionnaires allow assessing quality of life disturbances by cerebral palsy and use these data for dynamic observation during the treatment. The article presents the most objective studies of the quality of life with cerebral palsy. Pain in patients with cerebral palsy is a serious problem and has a significant negative impact on the quality of life. It has been shown that injections of botulinum toxin type A can not only lead to pain reduction, but significantly improve the functioning of patients with cerebral palsy and improve their quality of life. It is equally important to assess the quality of life of parents and relatives of sick children. There is evidence that severe motor disorders by cerebral palsy have a significant negative impact on the quality of life and the development of depression by mothers who take care of a child.


  • Open Access

    Russian consensus on the use of incobotulinumtoxinA in children with cerebral palsy for the treatment of spasticity and sialorrhea

    by A. L. Kurenkov, L. M. Kuzenkova, B. I. Bursagova, V. V. Chernikov, O. V. Agranovich, L. G. Khachatryan, V. M. Kenis, V. A. Zherebtsova, M. N. Sarzhina, N. D. Odinaeva, et al.

    Botulinum therapy for cerebral palsy (CP) is considered not only as one of the effective approaches for the treatment of increased muscle tone and spasticity, but also as a method of excessive salivation correction. The article presents an overview of the results of Russian and foreign studies on the efficacy and safety of incobotulinumtoxinA for the treatment of spasticity of the lower and upper limbs, as well as sialorrhea in patients with CP. The article also provides a consensus opinion of Russian specialists working with patients with CP and using Xeomin (incobotulinumtoxinA) in their practice for the treatment of spasticity and sialorrhea. This consensus was based on the results of a Russian retrospective multicenter study on the use of incobotulinumtoxinA for the treatment of spasticity and sialorrhea in CP, data from recently published international clinical trials, and our own clinical experience. We present detailed practical recommendations on the calculation of the total dose of incobotulinumtoxinA per procedure for the treatment of spasticity in CP, on the calculation of incobotulinumtoxinA dose for the most common target muscles (lower and upper limbs) for spasticity treatment in CP, on incobotulinumtoxinA dilution and dose calculation for sialorrhea treatment in children, on incobotulinumtoxinA dilution and dose calculation for simultaneous treatment of spasticity and sialorrhea in CP. We justify incobotulinumtoxinA use, when simultaneous treatment of spasticity and sialorrhea is necessary, which allows reducing the intervals between repeated injection cycles. IncobotulinumtoxinA use in children with CP demonstrates a favorable safety profile, including long-term use.


  • Open Access

    Safety profile of onasemnogene abeparvovec in children with spinal muscular atrophy

    by Lyudmila M. Kuzenkova, Evgeniya V. Uvakina, Sofiya G. Popovich, Tatyana V. Podkletnova, Aleksandra A. Nezhelskaya, Luizat M. Abdullaeva, Darya A. Fisenko, Alena V. Naidenko

    Goal. To evaluate the safety profile of onasemnogene abeparvovec (Zolgensma®) gene therapy in children with spinal muscular atrophy (SMA) in real clinical practice. Materials and methods. The study included 30 SMA children who underwent gene replacement therapy with onasemnogene abeparvovec (Zolgensma®) from December 2020 to December 2021 at the Center for Pediatric Psychoneurology. All children had a diagnosis of SMA confirmed by molecular genetic methods, with no more than 3 copies of the SMN2 gene and the absence of antibodies to the adeno-associated virus serotype 9. The safety profile was assessed by monitoring the clinical and laboratory data of the patients after administration of onasemnogene abeparvovec. Clinical events included all changes in the child’s condition that could be associated with the administration of the drug (hyperthermia, decreased appetite, nausea, vomiting, stool disorders). Laboratory assessment included monitoring of complete blood count, biochemical blood tests, blood coagulation indices. The degree of laboratory changes was estimated according to common terminology criteria for adverse events (CTCAE version 5.0). Results. The safety profile of the drug Zolgensma® was studied in 30 children aged from 3 to 39 months, with a weight of 5.2 kg to 14.2 kg. Twenty-eight (93.3%) children had at least one clinical event associated with the administration of the drug. Hyperthermia was observed in 24 (80%) children, nausea and vomiting in 18 (60%) children, decreased appetite in 20 (66.7%) children, stool changes in 4 (13.3%) children. Monitoring of laboratory indices revealed thrombocytopenia and monocytosis in twenty-two (73.3%) children and neutropenia in twelve (40%) children in the general blood test. An increase in the level of transaminases was noted in all children, the CTCAE grade 1 was detected in fifteen (50%) children, the CTCAE grade 2 in 7 (23.3%) children, CTCAE grade 3 in 6 (20%) children, CTCAE grade 4 in 2 (6.7%) children. Children with CTCAE grade 3 required correction of the prednisone dose up 2 mg/kg per day for 2-4 weeks. Two children with CTCAE grade 4 required pulse therapy with methylprednisolone at a dose of 30 mg/kg per day. Regardless of the level of transaminases, no change in the level of total and direct bilirubin was observed in any case. A decrease in prothrombin time was observed in 14 (46.6%) children. An increase in the level of troponin I was detected in four (13.3%) children. In all cases of serious adverse events, according to laboratory indices, the clinical condition of the children remained stable. The average duration of prednisone intake was 17.8 ± 6.6 weeks. Conclusion. The safety profile of the drug onasemnogene abeparvovec (Zolgensma®) in real clinical practice in children with SMA is presented.


  • Dose selection of Incobotulinumtoxin A for the treatment of spasticity and sialorrhea in cerebral palsy: results of a retrospective multicenter study

    by Алексей Львович Куренков, Oleg V. Agranovich, Lyudmila M. Kuzenkova, Lusine G. Khachatryan, Vladimir M. Kenis, Valentina A. Zherebtsova, Marina N. Sarzhina, Niso D. Odinaeva, Ada R. Artemenko, Galina A. Popova, et al.

    Introduction. In patients with infantile cerebral palsy (CP), botulinum therapy is used to treat both muscle tone disorders and sialorrhea. Therefore, it is logical to use one preparation of botulinum toxin type A to treat spasticity and sialorrhea in one injection procedure. The aim of the work is to conduct a retrospective analysis of data from 15 centres that treat patients with cerebral palsy and use the botulinum therapy method to determine the optimal doses of IncobotulinumtoxinA (IBTA) for the treatment of spasticity and chronic sialorrhea in real clinical practice. Materials and methods. The treatment results of 389 children with cerebral palsy (including 211 (54.2%) boys) with IBTA were analyzed. The majority were children with bilateral forms of cerebral palsy - 312 (80.2%). The average age of the patients was 5.27 ± 3.71 years, the average weight of the patients was 18.8 ± 10.9 kg. Results. The total dose of IBTA in the group of 389 patients with cerebral palsy for the treatment of spasticity was 163.74 ± 80.65 U (25-550; 95% CI 155.7-171.7) and 10.4 ± 5.4 U/kg body weight (1,25-29.7; 95% CI 9.8-10.9). The total dose of IBTA in the group of patients with cerebral palsy with simultaneous treatment of spasticity and chronic sialorrhea (n = 16) was significantly higher: 267.18 ± 124.57 U (115-570; 95% CI 200.8-333.6) and 13, 0 ± 7.1 U/kg (5.8-24.6; 95% CI 9.2-16.8). In the lower extremities, the most frequent target muscles were the gastrocnemius (55.0% of cases; 95% CI 49.9-60.0) and semitendinosus / semimembranous muscle (46.3% of cases; 95% CI 41.2-51.4 ), and in the upper limbs - pronator teres (48.6% of cases; 95% CI 43.5-53.7) and biceps brachii (28.8% of cases; 95% CI 24.3-33.6). Limitations of the study. The limitations of our work are the use of an open retrospective study format, a relatively small sample of patients with chronic sialorrhea, the absence of long-term follow-up of patients and the results of repeated IBTA injections. Conclusion. If it is necessary to use botulinum therapy for the treatment of spasticity and sialorrhea in a child with CP, it is optimal to use the product IncobotulinumtoxinA, which will allow correction of two pathological manifestations in one procedure and can shorten the intervals between repeated injection cycles.